- Home
- TMTS vs ABEO Comparison
TMTS vs ABEO Comparison
Compare TMTS & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TMTS | ABEO |
|---|---|---|
| Founded | 2025 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.7M | 282.5M |
| IPO Year | 2025 | 2005 |
Fundamental Metrics
Financial Performance| Metric | TMTS | ABEO |
|---|---|---|
| Price | $10.02 | $4.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $18.88 |
| AVG Volume (30 Days) | 306.1K | ★ 1.0M |
| Earning Date | N/A | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $804.33 |
| Revenue Next Year | N/A | $119.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $9.99 | $4.00 |
| 52 Week High | $10.09 | $7.65 |
Technical Indicators
Market Signals| Indicator | TMTS | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 50.25 | 45.43 |
| Support Level | N/A | $4.26 |
| Resistance Level | $10.04 | $5.91 |
| Average True Range (ATR) | 0.01 | 0.22 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 66.67 | 60.90 |
Price Performance
Historical ComparisonAbout TMTS Spartacus Acquisition Corp. II Class A Ordinary Shares
Spartacus Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.